Unlocking Optimal Strategies in Treating DED: Evaporation Is Key (Online CE Monograph)

Activity Description and Purpose

Most people with dry eye disease (DED) have the evaporative subtype, for which meibomian gland dysfunction is the leading cause. Recent advances in options for managing DED include US Food and Drug Administration–approved and emerging therapies that introduce novel mechanisms of action. This educational activity is based on the proceedings of a live CE symposium that took place on October 11, 2023, in New Orleans, Louisiana. This activity will present an overview of DED pathophysiology, which will provide a foundation for targeted treatment selection, results from clinical trials of new and emerging treatments, and a series of case-based discussions. The desired results of this activity are to cement clinicians’ knowledge of the role of evaporation in the pathogenesis of meibomian gland dysfunction and help them obtain practical strategies for screening, diagnosis, and effective treatment that can improve patient outcomes

Target Audience

This educational activity is intended for optometrists.

Learning Objectives

After completing this activity, participants will be better able to:

  • Review the function of the tear film in maintaining a healthy ocular surface
  • Review clinical evidence of approved treatments for dry eye disease 
  • Design evidence-based treatment plans for patients with dry eye disease
Course summary
Available credit: 
  • 2.00 COPE
Course opens: 
Course expires: 


Kelly K. Nichols, OD, MPH, PhD, FAAO (Chair)
University of Alabama at Birmingham School of Optometry
Birmingham, Alabama
Jaclyn Garlich, OD, FAAO
Envision Optometry
Boston, Massachusetts
Paul Karpecki, OD, FAAO
Director, Cornea and External Disease
Kentucky Eye Institute
Lexington, Kentucky
Associate Professor
University of Pikeville School of Optometry
Pikeville, Kentucky

Selina McGee, OD, FAAO
Visionary Founder/Owner
BeSpoke Vision
Edmond, Oklahoma

Disclosure Policy

MedEdicus requires that anyone who is in a position to control the content of this educational activity disclose all relevant financial relationships with any commercial interest. Financial relationship information is collected and resolved prior to the educational activity. All relevant relationships have been mitigated.


Jaclyn Garlich, OD, is a consultant for Lumenis, Ophthalmic Resources Partners, Orasis Pharmaceuticals, Tarsus Pharmaceuticals, Inc, and Thea Pharmaceuticals Limited; is an advisory board member of Aldeyra Therapeutics, Bruder Healthcare, and Novartis Pharmaceuticals Corporation; and is on the speakers bureau for AbbVie Inc.

Paul Karpecki, OD, is a consultant for AbbVie Inc, AdOM Optical Technologies Ltd, Akorn, Inc*, Alcon, Aldeyra Therapeutics, Ametek, Inc*, Apellis Pharmaceuticals, Astellas Pharma Inc, Atlas Medical GmbH, Aurion Biotechnologies, Avellino, Azura Ophthalmics, Bausch & Lomb Incorporated, Bio-Tissue, BlephEx*, Bruder Healthcare, Bruno Vision, Cambium Medical Technologies*, Dompé US, Inc, Eyedetec Medical, Eyesafe, Gobiquity*, Haag-Streit Group*, Hilco Vision*, Horizon Therapeutics plc, iCare USA Inc*, Imprimis Pharmaceuticals, Inc, Kala Pharmaceuticals*, Keplr Vision*, Kiora Pharmaceuticals, Inc*, Konan Medical USA, Inc, Lentechs, MacuLogix, Inc*, Neurolens, Novartis Pharmaceuticals Corporation, OASIS Medical, OCULUS, Inc, OcuMedic, Inc, Ocuphire Pharma, OCuSOFT Inc, Olympic Ophthalmics Inc, Optase*, Orasis Pharmaceuticals, Oyster Point Pharma, Inc*, Regener-Eyes, Reichert, Inc, Rendia, Inc, RVL Pharmaceuticals, Inc, RxSIGHT, Santen Inc, ScienceBased Health, Scope, Sentiss Pharma Pvt Ltd, Sight Sciences, Silk Technologies Ltd, StepWise Medical*, Sun Pharmaceutical Industries, Inc, Surface Pharmaceuticals Inc, Sydnexis Inc, Tarsus Pharmaceuticals, Inc, TearClear, Thea Pharmaceuticals Limited, Vial, Viatris Inc, Visant Medical, Inc, Vital Tears LLC, and Zeiss*; is an advisory board member of AstaReal, Inc*; and is on the speakers bureau for Aerie Pharmaceuticals, Inc*, Bausch & Lomb Incorporated, Dompé US, Inc, Johnson & Johnson Vision Care, Inc*, Mallinckrodt, and Sun Pharmaceutical Industries, Inc.

Selina McGee, OD, is a consultant for AbbVie Inc, Aldeyra Therapeutics, Avellino, Bruder Healthcare, Cynosure, Dompé US, Inc, Eyevance, Harrow, Horizon Therapeutics plc, Kala Pharmaceuticals, Lumenis, Novartis Pharmaceuticals Corporation, Ocuphire Pharma, Optovue, Incorporated, Oyster Point Pharma, Inc, RVL Pharmaceuticals, Inc, ScienceBased Health, Sun Pharmaceutical Industries, Inc, Tarsus Pharmaceuticals, Inc, Thea Pharmaceuticals Limited, Topcon, Trukera, and Versant Ventures; and is on the speakers bureau for AbbVie Inc, Bausch & Lomb Incorporated, Cynosure, Dompé US, Inc, Lumenis, Optovue, Incorporated, Oyster Point Pharma, Inc, and Tarsus Pharmaceuticals, Inc.

Kelly K. Nichols, OD, MPH, PhD, is a consultant for AbbVie Inc, Aerie Pharmaceuticals, Inc Alcon, Aldeyra Therapeutics, Axim Biotech, Azura Ophthalmics, Bausch & Lomb Incorporated, Bruder Healthcare, Dompé US, Inc, HanAll Biopharma, Nicox, Novaliq GmbH, Novartis Pharmaceuticals Corporation*, Osmotica Pharmaceuticals plc*, RVL Pharmaceuticals, Inc*, Oyster Point Pharma, Inc*, Palatin Technologies, Inc*, Takeda Pharmaceuticals USA, Inc*, Tarsus Pharmaceuticals, Inc, TearSolutions*, Thea Pharmaceuticals Limited, TopiVert Ltd*, Trukera Medical, Verséa Health, Inc, and Xequel Bio; is on the speakers bureau for Bausch & Lomb Incorporated; is a contracted researcher for Aramis Biosciences, KOWA Pharmaceuticals America, Inc, Sight Sciences, Sylentis, SA, and TearScience; and has individual stocks or stock options in Axim Biotech and Oyster Point Pharma, Inc*.

* The financial relationship existed during the last 24 months but has now ended

Planners, Managers, and Writers

MedEdicus planners, managers, and writers have no relevant commercial relationships to disclose.

Accreditation Statement

 COPE approved for 2.0 CE credits for optometrists.
COPE Course ID: 90546-TD (Asynchronous)
COPE Course Category: Treatment/Management of Ocular Disease


This activity, COPE Activity Number 128064, is accredited by COPE for continuing education for optometrists.

Disclosure of Commercial Support

MedEdicus LLC has received commercial support from Bausch & Lomb Incorporated for this activity in the form of an unrestricted educational grant.

The content of this COPE-Accredited CE activity was planned and prepared independently by MedEdicus LLC without input from members of an ineligible company.

Off-Label Discussion

This educational activity may include discussion of unlabeled and/or investigational uses of drugs and devices. Please refer to the official prescribing information for each drug or device discussed in this activity for approved dosing, indications, and warnings.

Sponsored by

Contact Information

For questions about this educational activity, please contact MedEdicus LLC at info@mededicus.com.

To view the MedEdicus privacy policy, visit http://mededicus.com/privacy-policy.php


The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of the State University of New York College of Optometry, MedEdicus LLC, or Bausch & Lomb Incorporated.

This CE activity is copyrighted to MedEdicus LLC ©2024. All rights reserved. MedEdicus does not claim copyright to material included herein owned by third parties for which attribution or citation has been made. 302.4b

Available Credit

  • 2.00 COPE
Please login or register to take this course.

Clicking Register/Take course indicates that you have reviewed the CE information for this activity.